ENDRA Life Sciences (NASDAQ: NDRA) Advances TAEUS Registered Liver Imaging, Strengthens Capital Efficiency; WVE, TWG, BDRX, FULC Also Active

ENDRA Life Sciences (NASDAQ: NDRA) is redefining how emerging health-tech companies accelerate breakthrough innovation while maintaining disciplined capital efficiency. The developer of TAEUS Registered (Thermo-Acoustic Enhanced UltraSound) has implemented a modern treasury strategy managed by Arca Investment Management, converting idle cash into a structured, yield-generating engine that supports long-term growth without shareholder dilution.

Along with ENDRA Life Sciences Inc (NASDAQ: NDRA), see SmallCap Stocks to Watch Now: Biodexa Pharmaceuticals (NASDAQ: BDRX), Wave Life Sciences (NASDAQ: WVE), Top Wealth Group Ltd (NASDAQ: TWG),and Fulcrum Therapeutics (NASDAQ: FULC), all active in intraday trading sessions.

TAEUS Registered is designed to offer CT- or MRI-like insights into liver fat composition directly at the point of care, providing clinicians with a fast, cost-effective alternative for diagnosing and monitoring steatotic liver disease (SLD) and MASH-conditions that affect more than 2 billion people worldwide. With demand rising sharply alongside GLP-1 therapy adoption, scalable liver monitoring solutions are becoming essential across clinical care and drug development.

Latest Clinical Data Strengthens TAEUS Registered 's Position as an MRI-PDFF Alternative

ENDRA recently announced new feasibility study results demonstrating that TAEUS Registered 's thermo-acoustic fat fraction (TAFF) measurement closely aligns with MRI-PDFF performance at key clinical thresholds, including the 12-17% and 20-22% liver fat cutoffs used to classify mild, moderate, and severe disease.

Key Performance Metrics:

* 12-17% LFF: PPV 100%, NPV 94%, Accuracy 95%
* 20-22% LFF: PPV 90%, NPV 94%, Accuracy 94%

These thresholds guide clinical therapy decisions, reimbursement qualification, and patient stratification for MASLD/MASH clinical trials. The high PPV and NPV demonstrate TAEUS Registered 's potential as a low-cost, point-of-care alternative to MRI-PDFF, which often exceeds $2,500 per scan.

A second feasibility study is now underway in London, Ontario, with results expected in the coming months.

Financial Innovation Supporting Clinical Acceleration

ENDRA's partnership with Arca introduces an institutional-grade treasury framework that generates consistent, non-dilutive returns through professionally managed financial instruments. This strengthens ENDRA's operating runway while supporting clinical validation, regulatory engagement, and commercialization planning.

Positioned for Significant Market Impact

By uniting breakthrough imaging technology with a forward-looking treasury model, ENDRA is positioned to drive adoption across both clinical care and pharmaceutical development. TAEUS Registered could significantly reduce imaging costs and increase monitoring frequency in MASLD/MASH and GLP-1 drug trials-creating meaningful value for biopharma partners and healthcare systems.

As the Company progresses toward additional validation studies and future regulatory milestones, ENDRA Life Sciences represents a differentiated opportunity for investors, clinicians, and biopharma partners seeking scalable, accessible, and cost-effective solutions in metabolic liver disease.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=endra-life-sciences-nasdaq-ndra-advances-taeus-liver-imaging-strengthens-capital-efficiency-wve-twg-bdrx-fulc-also-active]
Country: United States
Website: http://www.thestreetreports.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.